"Haphazard trial design doesn't cut it for development of cardiovascular risk predictors, the American Heart Association said. Given the proliferation of proposed genetic, imaging, and biological markers and recent debate over C-reactive protein, a scientific statement from the association laid down the basics for evaluation of new markers of cardiovascular risk"
No comments:
Post a Comment